BRIEF-Oncolytics reports additional data from phase II study of Reolysin
Aug 10 (Reuters) - Oncolytics Biotech Inc
* Oncolytics Biotech Inc. reports additional data from randomized phase II study of Reolysin in non-small cell lung cancer
* Study demonstrates statistically significant improvement in progression free survival in female patients with Adenocarcinoma
* Based on findings from IND 211, intends to include preselection of patients using genetic screening in future study protocols Source text for Eikon: Further company coverage:
© Thomson Reuters 2017 All rights reserved.